ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview

ProQR Therapeutics NV

31/07/2023 19:35

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 2
(estimated). 
    * The Leiden Zuid-holland-based  company is expected to
report  a
18.8% increase in revenue to €1.218 million from €1.03 million a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ProQR Therapeutics
NV is
for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $4.75​, above​ its last closing price
of $1.53. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.09       -0.12      -0.11     Beat    6.5
 Dec. 31 2023  -0.17       -0.18      -0.16     Beat    10.4
 Sep. 30 2022  -0.19       -0.21      -0.34     Missed  -61.5​
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    2.7
 ​​Mar.        -0.24       -0.24      -0.20     Beat    15.1
 31 2022                                                
 Dec. 31 2021  -0.18       -0.19      -0.26     Missed  -40​
 Sep. 30 2021  -0.20       -0.21      -0.22     Missed  -7.3
 Jun. 30 2021  -0.22       -0.24      -0.24     Met     -1.2
 This summary was machine generated July 31 at 18:35 GMT.  All
figures in euros  unless otherwise stated